NCT07200622View on ClinicalTrials.gov

Oral Semaglutide in Patients With Alzheimer's Disease

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 25, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Alzheimer Disease
Interventions
DRUG

Semaglutide (Rybelsus®)

All subjects will receive oral semaglutide once daily (4-weekly dose escalation from 3 mg to 7 mg and finally 14 mg). This dose escalation schedule is specified in the IMP (Rybelsus) SmPC.

DRUG

Placebo

Matched oral Placebo to be taken once daily.

All Listed Sponsors
lead

Imperial College London

OTHER